article thumbnail

Anthos Presents New Analysis from P2 AZALEA-TIMI 71 Study

DAIC

Patient Demographics: Patients on APT had a higher rate of coronary artery disease (70% vs. 42%), previous heart attacks (36% vs. 16%), and peripheral artery disease (15% vs. 11%). For more information, please visit anthostherapeutics.com.

article thumbnail

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

article thumbnail

Chronic exposure to lead, cadmium and arsenic increases risk of cardiovascular disease

Science Daily - Stroke

Around the world, most people are regularly exposed to low or moderate levels of lead, cadmium and arsenic in the environment, increasing risk of coronary artery disease, stroke and peripheral artery disease, according to a new statement.

article thumbnail

Prevalence of Peripheral Arterial Disease in Patients With Coronary Artery Disease After Cardiac Catheterization: A Prospective Observational Study

The American Journal of Cardiology

Publication date: 15 January 2024 Source: The American Journal of Cardiology, Volume 211 Author(s): Sanjot S. Sunner, Robert C. Welsh, Kevin R.

article thumbnail

Elixir Medical Receives FDA Breakthrough Device Designation for DynamX BTK System for Below-The-Knee Arterial Disease

DAIC

The company reports this broadens the use of the novel bioadaptor platform technology beyond the treatment of coronary artery disease. Peripheral arterial disease ( PAD ) affects more than 200 million people worldwide. Glob Heart. 2014;9(1):145-158 e121. 2013;382(9901):1329-1340.

article thumbnail

Johnson and Johnson Completes Acquisition of Shockwave Medical

DAIC

This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention.

article thumbnail

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

DAIC

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Journal of Vascular Surgery, Mar.